0
Galecto, Inc. Banner Image

Galecto, Inc.

  • Ticker GLTO
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Galecto, Inc. Logo Image
  • 11-50 Employees
  • Based in Copenhagen, Denmark
Galecto is a clinical stage company incorporated in the U.S. that is developing small molecule-based inhibitors of galectin-3 and LOXL2. Galecto has multiple ongoing Phase 2 clinical programs in fibrosis and cancer, including (i) an orally active LOXL2 inhibitor (GB2064) in a Phase 2a trial for the treatment of myelofibrosis; (ii) an orally active galectin-3 inhibitor (GB1211) in a recentlyMore completed Phase 1b/2a trial in liver cirrhosis; and (iii) an orally active galectin-3 inhibitor (GB1211) in combination with atezolizumab (Tecentriq®) in a separate Phase 2a trial for the treatment of NSCLC.
Galecto, Inc.

Most Recent Annual Report

Galecto, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Galecto, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!